GlassScriptPhysician profile
Abdalsamih M Taeb
NPI 1487941597
$10,258.50
in general payments reported to CMS, 2019-2025
39 companies · $6,858 in 2025
The $6,858 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $244 · 2021: $273 · 2022: $715 · 2023: $868 · 2024: $1,302 · 2025: $6,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Food and Beverage: $3,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Food and Beverage | $3,527.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,516.99 | 2025 | |
| Glaxosmithkline, LLC. | $960.99 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $621.22 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.34 | 2020-2025 | Ofev, Jascayd, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $463.29 | 2021-2024 | Fasenra, Tezspire, Airsupra |
| Ani Pharmaceuticals, INC. | $421.16 | 2023-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $281.31 | 2021-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $147.28 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $127.01 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $118.31 | 2020-2024 | Yupelri |
| Daiichi Sankyo INC. | $100.36 | 2024-2025 | Enhertu |
| United Therapeutics Corporation | $96.25 | 2022-2024 | Tyvaso |
| Amgen INC. | $78.04 | 2024-2025 | Tezspire |
| Insmed, INC. | $60.26 | 2022-2023 | Arikayce |
| Mallinckrodt Hospital Products INC. | $59.04 | 2024 | Acthar |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $50.54 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $48.74 | 2020-2023 | |
| Actelion Pharmaceuticals US, INC. | $47.19 | 2022-2025 | Uptravi, Opsumit |
| Csl Behring | $45.07 | 2025 | Hizentra |
| Electromed, INC. | $44.11 | 2025 | Smartvest |
| Pulmonx Corporation | $40.79 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $38.49 | 2022-2025 | Glassia |
| Alexion Pharmaceuticals, INC. | $35.51 | 2021-2023 | Ultomiris |
| Gilead Sciences, INC. | $33.62 | 2022-2024 | Veklury |
| Advanced Respiratory, INC | $33.38 | 2020-2021 | |
| Ethicon INC. | $30.35 | 2025 | Monarch Platform |
| Sanofi Pasteur INC. | $29.48 | 2024 | |
| Viatris Specialty LLC | $28.54 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $28.42 | 2025 | Inspire |
| Shionogi INC | $25.98 | 2022 | |
| Baxter Healthcare | $22.36 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $18.80 | 2024 | (Ak6) Vest Therapy |
| Bayer Healthcare Pharmaceuticals INC. | $18.24 | 2023 | |
| La Jolla Pharmaceutical Company | $17.55 | 2020 | |
| Olympus America INC. | $16.34 | 2022 | |
| Resmed Corp | $15.46 | 2023 | |
| Chiesi USA, INC. | $15.01 | 2020 | |
| Inogen, INC. | $14.89 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pfizer INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdalsamih Taeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.